Education
About Us
Working with TipRanks
Follow Us
Elixinol Wellness (ELLXF)
OTHER OTC:ELLXF
ELLXF Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.04
Previous CloseN/A
Volume25.00
Average Volume (3M)5.17K
Market Cap
$2.37M
Enterprise Value$4.28M
Total Cash (Recent Filing)$1.41M
Total Debt (Recent Filing)$3.95M
Price to Earnings (P/E)―
Beta-3.29
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding413,987,730
10 Day Avg. Volume617
30 Day Avg. Volume5,165
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.15
P/FCF Ratio-0.70
Enterprise Value/Market Cap1.81
Enterprise Value/Revenue0.28
Enterprise Value/Gross Profit1.38
Enterprise Value/Ebitda-0.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Shift To Higher‑margin Revenue MixA sustained reweighting to e-commerce (21%→38%) and reduction of low‑margin bulk improves gross margin potential and revenue stickiness. Higher D2C mix should raise lifetime value, increase pricing control and predictability, supporting durable cash generation if channel momentum continues.
Structural Cost Reduction And Q4 Cash ProfitabilityA permanent ~30% OpEx reduction materially lowers the break‑even run rate. Achieving slightly positive quarterly EBITDA and positive normalized operating cash flow demonstrates the business can reach operational self‑sufficiency, reducing financing dependence and enabling reinvestment or M&A to scale growth sustainably.
Hemp Platform Scale And Contracted VolumesPositioning as Australia’s largest hemp brand and ingredient supplier with contracted volumes gives vertical integration and supply security. This creates margin protection, B2B customer lock‑in and barriers for smaller rivals, supporting stable input costs and a platform for scaling premium private‑label and branded sales.
Bears Say
Persistent Negative Operating And Free Cash FlowOngoing annual cash burn, including ~-A$3.2M OCF in 2025, erodes equity and forces reliance on external capital. Persistent negative cash flow constrains capex, marketing investment and M&A execution, and makes the company vulnerable to funding shocks if revenue or margin improvements stall.
Small Absolute Revenue Base And Modest GrowthA$15.5M revenue and single‑digit growth limit scale economies and operating leverage. The small base magnifies the impact of lost retail listings or weaker seasonal demand, constrains bargaining power with large retailers, and reduces capacity to fund sustained marketing or product investment needed for durable market share gains.
Brand And Channel Concentration; Supermarket PressureHeavy concentration (≈75% from three brands) and dependence on tough supermarket channels heighten revenue volatility. Range rationalisation and underperformance of a key brand can quickly dent sales and margins, weakening predictability of cash flows and exposing the business to retailer decisions beyond management control.
Elixinol Wellness News
ELLXF FAQ
What was Elixinol Wellness’s price range in the past 12 months?
Elixinol Wellness lowest stock price was <$0.01 and its highest was $0.04 in the past 12 months.
What is Elixinol Wellness’s market cap?
Elixinol Wellness’s market cap is $2.37M.
When is Elixinol Wellness’s upcoming earnings report date?
Elixinol Wellness’s upcoming earnings report date is Aug 27, 2026 which is in 168 days.
How were Elixinol Wellness’s earnings last quarter?
Elixinol Wellness released its earnings results on Feb 12, 2026. The company reported -$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.006.
Is Elixinol Wellness overvalued?
According to Wall Street analysts Elixinol Wellness’s price is currently Overvalued.
Does Elixinol Wellness pay dividends?
Elixinol Wellness does not currently pay dividends.
What is Elixinol Wellness’s EPS estimate?
Elixinol Wellness’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elixinol Wellness have?
Elixinol Wellness has 413,987,730 shares outstanding.
What happened to Elixinol Wellness’s price movement after its last earnings report?
Elixinol Wellness reported an EPS of -$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 50%.
Which hedge fund is a major shareholder of Elixinol Wellness?
Currently, no hedge funds are holding shares in ELLXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elixinol Wellness Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth AU$3.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-76.30%
Trailing 12-Months
Asset Growth
-6.80%
Trailing 12-Months
Company Description
Elixinol Wellness
Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes hemp derived nutraceuticals, cosmetics, and food products under the Elixinol and Hemp Foods Australia brands in the Americas, Europe, and Australia. It offers hemp derived cannabidiol and food products, dietary supplements, topicals, and skincare products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is headquartered in Sydney, Australia.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---